ASX/IXC (ASX/IXC)

Australian Securities Exchange: ASX/IXC · AUD

A$0.10

+0.00 (0.0%)· Recorded snapshot

Market cap	7.5M
Revenue (ttm)	46.8K
Net income (ttm)	-1.4M
EPS (ttm)	-A$0.02
Shares out	75.2M
Volume	86,747
Beta	0.52

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 46.8K
Net income (ttm): -1.4M
EPS (ttm): -A$0.02
Market cap: 7.5M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-30 13:30 UTC

Forward P/En/a

P25 14.6P50 21P75 31.9

Trailing P/En/a

P25 15.4P50 29.4P75 64.4

ROE-29.5

P25 -108P50 -50.6P75 1.1

ROIC-20.4

P25 -64.5P50 -33.5P75 0.8

Benchmarks · 1M

All ASX/IXC indicators

Market & fundamental data

Available fields

156

Groups with data

Currency

AUD

Showing 156 of 156 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	AUD
Country	Australia
Country code	AU
Earnings date	2026-11-03
Enterprise value	AUD 3.5M
Exchange	Australian Securities Exchange
Financial currency	AUD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	June
Founded	2019
Industry	Biotechnology
Is primary listing	Yes
ISIN number	AU0000048621
Last earnings date	2026-02-05
Last refreshed	2026-10-30
Market cap	AUD 7.5M
Next earnings date	2026-11-03
Price	AUD 0.10
Price currency	AUD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	asx/IXC
Website	https://www.invextherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-18%
EV/Sales	74.73x
Industry forward P/E	29.15x
P/B ratio	1.92x
P/S ratio	160.5x
Price / tangible book value	1.92x
Sector forward P/E	34.28x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-3,198.22%
Pretax margin	-2,888.04%
ROA	-19.64%
ROA (5Y)	-13.01%
ROCE	-38.3%
ROE	-29.54%
ROE (5Y)	-18.94%
ROIC	-20.44%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-79.56%
Gross profit growth (Q)	-79.56%
Gross profit growth 3Y	-53.28%
Net income growth years	0
Revenue growth	-79.56%
Revenue growth (Q)	-79.56%
Revenue growth 3Y	-53.28%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	AUD -1.5M
EPS	AUD -0.02
Gross profit	AUD 46,826
Investing cash flow	AUD -2.5M
Net cash flow	AUD -3.9M
Net income	AUD -1.4M
Operating income	AUD -1.5M
Revenue	AUD 46,826

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	26.41
Book value per share	AUD 0.05
Debt / equity	0
Long-term assets	AUD 0
Long-term liabilities	AUD 0
Net cash (debt)	AUD 4M
Net cash / market cap	53.44%
Net cash growth	-25.28%
Net debt / equity	-1.03
Piotroski F-Score	1
Shareholders' equity	AUD 3.9M
Tangible book value	AUD 3.9M
Tangible book value per share	AUD 0.05
Total assets	AUD 4.1M
Total cash	AUD 4M
Total debt	AUD 0
Total liabilities	AUD 153,471
WACC	7.1%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	AUD 4.1M
Current liabilities	AUD 153,471
Current ratio	26.48
Net working capital	AUD -106,141
Quick ratio	26.48
Working capital	AUD 3.9M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.74%
Dividend per share	AUD 0.00
Last dividend	AUD 0.19
Shareholder yield	0.74%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	AUD 0.12
1D price change	0%
1M price change	-9.09%
1M total return	-9.09%
1W price change	-16.67%
1W total return	-16.67%
1Y price change	-23.08%
1Y return CAGR	-23.09%
1Y total return	-23.08%
20-day SMA	AUD 0.11
200-day SMA	AUD 0.11
3M price change	-16.67%
3M total return	-16.67%
3Y price change	-50%
3Y return CAGR	25.19%
3Y total return	96.23%
50-day SMA	AUD 0.11
50-day SMA vs 200-day SMA	50under200
52-week high	AUD 0.15
52-week high date	2025-11-13
52-week low	AUD 0.09
52-week low date	2026-06-30
5Y price change	-85.4%
5Y return CAGR	-10.54%
5Y total return	-42.71%
All-time high	AUD 2.05
All-time high date	2020-05-22
All-time low	AUD 0.06
All-time low date	2025-03-13
Average true range (ATR)	AUD 0.01
Average volume	86.1K
Beta (1Y)	0.49
Beta (2Y)	-0.19
Beta (5Y)	0.52
Change from 52-week high	-33.33%
Change from 52-week low	11.11%
Change from all-time high	-95.12%
Change from all-time low	69.49%
Change from open	0%
Day's gap	0%
Dollar volume	AUD 8,675
High price	AUD 0.10
Low price	AUD 0.10
Monthly RSI	43.66
Open price	AUD 0.10
Previous close	AUD 0.10
Price vs 150-day SMA	-13.87%
Price vs 20-day SMA	-11.5%
Price vs 200-day SMA	-12.36%
Price vs 50-day SMA	-11.27%
Relative volume	1.01
RSI	43.14
Sharpe ratio	0.81
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	0.12
Sortino ratio	1.43
Sortino ratio (3Y)	0.71
Sortino ratio (5Y)	0.25
Volume	86.7K
Weekly RSI	45.72
YTD price change	-16.67%
YTD total return	-16.67%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46.6M
Shares change (QoQ)	-0.51%
Shares change (YoY)	-0.74%
Shares held by insiders	22.44%
Shares held by institutions	21.18%
Shares outstanding	75.2M

Deeper analysis on ASX/IXC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ASX/IXC report

Is a complete ASX/IXC research report available?

No complete published report is available for asx/IXC (ASX/IXC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ASX/IXC (ASX/IXC)

Price

Financial snapshot

Fair-value bridge

Latest news · ASX/IXC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ASX/IXC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ASX/IXC

Frequently asked questions